Here’s my video update for Thursday, December 3, in which I answer reader inquiries on a range of investment topics.

Readers have found all sorts of ways to reach me; the fastest and easiest method is to simply send an email to: mailbag@investingdaily.com. To subscribe to my video channel, follow this link.

Let’s review the latest questions that have come in over the transom. My answers strive to provide universal applicability for all types of investors.

Take a byte out of cyber crime…

“What’s your view of the cyber security sector? Is it a good play for 2021?” — Alex Z.

I’m bullish on cyber security stocks for next year and beyond. Major companies in cyber security are tapped into unstoppable momentum.

Hacking is proliferating around the globe, as cyber criminals and spies increasingly breach government agencies and heavily trafficked sites. They’ve posted customers’ sensitive information, including user names, passwords, e-mail addresses and device IDs, on the Internet for the world to see.

According to recent studies, information theft accounts for roughly 50% of corporate external costs on an annualized basis. That will fuel long-term demand for the products and services of companies in the cyber security sector.

Biden stocks…

“What do you see as the major investment themes of a Biden presidency?” — Alan G.

Despite its noisy aftermath, the 2020 election is over. Investors should position their portfolios for the inevitable transfer of power. In 2016, analysts wrote about “Trump stocks.” Now it’s time to write about “Biden stocks.”

Among the sectors that I particularly like for 2021 are infrastructure. You can expect massive fiscal stimulus next year that includes significant expenditures on roads, bridges, railroads, sewer systems, waterways, etc. There’s even a slight chance that we’ll get a “down payment” on stimulus before this year is over.

Read This Story: Get Ready for the “Do Something” Congress

It’s not just in America. Public works spending is a global theme; publicly traded construction firms with international footprints will thrive.

I also like renewable energy. The “Green New Deal” pushed by left-leaning Democrats faces difficult odds in a Senate dominated by GOP conservatives, but nonetheless a Biden administration is likely to prove friendly toward next-generation power sources such as solar, wind and biothermal.

Mind the GAAP…

“I see in many of your articles (and other commentators) comments about changes in earnings. The most recent mentions that blended earnings for the third quarter are on track for a decline of some 6%. My question is what earnings are you referring to? Is it GAAP earnings? It would help if you identified in your articles what method of calculating earnings you refer to.” — Kevin M.

Unless specified otherwise, our references to earnings are those on a GAAP (generally accepted accounting principles) basis.

Canna-billions at stake…

“Is cannabis really as big an investment theme as the financial media tell us?” — Kendra L.

Yes, indeed. Arcview Market Research and its research partner BDS Analytics estimate that spending on legal marijuana worldwide accelerated in 2019, soaring 38% to $16.9 billion, and should eventually reach $31.3 billion in 2022, growing at a 26.7% compound annual growth rate over the five-year frame from 2017. The estimates call for a $57 billion worldwide market by 2027.

Read This Story: A Divided America Finds Unity…On Weed

The U.S. House of Representatives is scheduled this week to take up legislation to legalize marijuana on the federal level, an historic step that could mark the first time a full congressional chamber has voted to end the federal government’s ban on marijuana.

The bill in question is the Marijuana Opportunity, Reinvestment and Expungement (MORE) Act, which would remove marijuana from the federal Controlled Substances Act and open up the industry to multibillion-dollar business opportunities and interstate commerce. The ramifications for marijuana businesses and investors are gigantic.

In fact, our team has unearthed a hidden gem in cannabusiness that most investors don’t even know about. This trailblazing small-cap biotech is offering an addiction-proof “marijuana pain pill” that’s about to end Big Pharma’s lock on harmful pain medications. This cannabis-based, non-opiate remedy could be the blockbuster pharmaceutical of the future.

The time to act is now, before this little-known company becomes a household name and its stock price goes ballistic. Click here for details.

If you’re interested in the latest political, regulatory, and investment news in the marijuana sector, be sure to read my twice-weekly e-letter, Marijuana Investing Daily.